RIBOLIFE-B(06938),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

06938 RIBOLIFE-B

Market Closed 01-23 16:08:26

78.700

-0.600

-0.76%

High80.850	Low77.500	Vol347.05K
Open80.000	D1 Closing79.300	Amplitude4.22%
Mkt Cap13.06B	Tradable Cap13.06B	Total Shares166.00M
T/O27.36M	T/O Rate0.21%	Tradable Shares166.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"RIBOLIFE-B","latestPrice":78.7,"timestamp":1769155706953,"preClose":79.3,"halted":0,"volume":347050,"delay":0,"changeRate":-0.007566204287515692,"floatShares":166000000,"shares":166000000,"eps":-1.855,"marketStatus":"Market Closed","change":-0.6,"latestTime":"01-23 16:08:26","open":80,"high":80.85,"low":77.5,"amount":27362300,"amplitude":0.042245,"askPrice":79.55,"askSize":600,"bidPrice":78.7,"bidSize":1400,"shortable":0,"etf":0,"ttmEps":-1.502,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1769391000000},"marketStatusCode":7,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":79.3,"openAndCloseTimeList":[[1769131800000,1769140800000],[1769144400000,1769155200000]],"volumeRatio":0.359540434705256,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06938/wiki","defaultTab":"wiki","newsList":[{"id":"1142220304","title":"RIBOLIFE-B (06938): RBD5044 Receives Implied Approval for Phase II Clinical Trial in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1142220304","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142220304?lang=en_us&edition=fundamental","pubTime":"2026-01-23 07:18","pubTimestamp":1769123896,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced that RBD5044 injection, independently developed by the group, has received implied approval from China's National Medical Products Administration for a Phase II clinical...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"gpt_icon":1},{"id":"1142966352","title":"Suzhou Ribo Life Science (6938) Announces Phase II Clinical Trial Approval for RBD5044","url":"https://stock-news.laohu8.com/highlight/detail?id=1142966352","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142966352?lang=en_us&edition=fundamental","pubTime":"2026-01-23 07:03","pubTimestamp":1769122985,"startTime":"0","endTime":"0","summary":"On January 23, 2026, Suzhou Ribo Life Science (6938) announced that its self-developed RBD5044 Injection received approval for a Phase II clinical trial from the National Medical Products...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"gpt_icon":0},{"id":"2605443278","title":"Suzhou Ribo Life Science Receives Phase II Trial Approval for RBD5044 in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2605443278","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605443278?lang=en_us&edition=fundamental","pubTime":"2026-01-23 07:00","pubTimestamp":1769122855,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on January 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL9wjWrJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"gpt_icon":0},{"id":"2605144322","title":"Suzhou Ribo Life Science Co Ltd - Rbd5044 Injection Approved for Phase Ii Clinical Trial in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2605144322","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605144322?lang=en_us&edition=fundamental","pubTime":"2026-01-23 07:00","pubTimestamp":1769122842,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nFWN3YN1DA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06938","BK1161"],"gpt_icon":0},{"id":"1182520230","title":"Hong Kong Stocks Movement | RIBOLIFE-B (06938) Rises Over 3% Before Noon, Pipeline Shows First-in-Class Potential with Lead in Phase 2 Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=1182520230","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182520230?lang=en_us&edition=fundamental","pubTime":"2026-01-15 12:00","pubTimestamp":1768449623,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) climbed more than 3% before noon. As of writing, the stock was up 2.63%, trading at HK$78.15, with a turnover of HK$48.3137 million. Public information indicates that RIBOLIFE is a...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"gpt_icon":0},{"id":"1157059158","title":"HK Movers | MiniMax Soars 90%, Ribo Surges 33%, Jinxun Resources Jumps 22% on Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=1157059158","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157059158?lang=en_us&edition=fundamental","pubTime":"2026-01-09 13:43","pubTimestamp":1767937427,"startTime":"0","endTime":"0","summary":"Chinese AI firm $MiniMax(00100)$ jumped 40% on debut in the Hong Kong.Founded in early 2022 by Yan Junjie, a former senior executive at SenseTime, MiniMax has positioned itself as a developer of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"382bff3444bfe0a1dcc26f0d5c6835da","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03636","00100","06938"],"gpt_icon":0},{"id":"2602349208","title":"Ribo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2602349208","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602349208?lang=en_us&edition=fundamental","pubTime":"2026-01-09 13:07","pubTimestamp":1767935220,"startTime":"0","endTime":"0","summary":"HONG KONG, Jan. 9, 2026 /PRNewswire/ -- Ribo Life Science Co., Ltd. , a leading company in small interfering RNA  therapeutics, today successfully listed on the Main Board of Hong Kong Stock Exchange, marking a significant milestone in the capitalization of Chinese biopharmaceutical enterprises in the siRNA field and injecting new momentum into the industry.Dr. Zicai Liang, Founder, Chairman and Chief Executive Officer of Ribo, commented: \"Listing on the Hong Kong Stock Exchange represents a major milestone in Ribo's journey. We extend our sincere gratitude to global investors for their trust and support. Moving forward, we will leverage the international capital markets to accelerate the global clinical development and commercialization of siRNA therapeutics, further strengthen our technologies, deliver breakthrough therapies to patients worldwide while creating sustainable value for shareholders.\"","market":"us","thumbnail":"https://mma.prnewswire.com/media/2858021/Ribo_Life.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2858021/Ribo_Life.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ribo-life-science-06938hk-successfully-lists-on-the-main-board-of-the-hong-kong-stock-exchange-302657128.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"gpt_icon":1},{"id":"1153176298","title":"Decoding RIBOLIFE-B (06938)'s Growth Trajectory: Robust Technological Barriers + Diversified Pipeline, Promising Commercial Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=1153176298","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153176298?lang=en_us&edition=fundamental","pubTime":"2026-01-09 12:49","pubTimestamp":1767934163,"startTime":"0","endTime":"0","summary":"The growth path of small nucleic acid industry giant Alnylam, which was \"a decade in the making,\" is expected to be replicated in the Hong Kong stock market. On January 9, RIBOLIFE-B (06938), a...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"gpt_icon":0},{"id":"2602492343","title":"Chinese Biotech, Metals Firm Jump in Hong Kong Trading Debuts","url":"https://stock-news.laohu8.com/highlight/detail?id=2602492343","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602492343?lang=en_us&edition=fundamental","pubTime":"2026-01-09 11:08","pubTimestamp":1767928080,"startTime":"0","endTime":"0","summary":"A biotech company and a metals processor made their Hong Kong debuts Friday, as the Asian financial hub's initial public offering market starts the year on a strong footing after reclaiming its position as the world's top fundraising venue in 2025.Shares of Suzhou Ribo Life Science's shares rose 21% to HK$70.25 in early trading from their listing price of HK$57.97. The company, which develops small nucleic acid drugs, raised HK$1.83 billion, equivalent to US$234.8 million.Yunnan Jinxun Resources, a Chinese non-ferrous metal processor, raised HK$1.10 billion in gross proceeds by selling 36.8 million shares. The company, which operates copper smelters in Africa, saw its shares climb 22% to HK$36.68 on Friday.Hong Kong's IPO market has maintained its momentum in the new year after reclaiming the top global spot for capital raised in 2025. The city raised HK$285.8 billion in 2025, a 225% increase from 2024, according to HKEX data.Hong Kong's IPO market could raise up to HK$350 billion in 2","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1128","06938"],"gpt_icon":1},{"id":"2602310897","title":"Suzhou Ribo Life Science Jumps 29% in Hong Kong Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2602310897","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602310897?lang=en_us&edition=fundamental","pubTime":"2026-01-09 09:49","pubTimestamp":1767923393,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science's (HKG:6938) shares opened 29.4% above their initial public offering price in a strong Hong Kong debut on Friday morning.The life sciences company opened at HK$75.00 per share, compared with the offer price of HK$57.97.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06938"],"gpt_icon":0},{"id":"1180247889","title":"Stock Track | RIBOLIFE-B Soars 24.12% in Intraday Trading on Strong Hong Kong Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=1180247889","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180247889?lang=en_us&edition=fundamental","pubTime":"2026-01-09 09:32","pubTimestamp":1767922349,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) surged 24.12% in intraday trading on Friday as the biotech startup made its highly anticipated debut on the Hong Kong Stock Exchange. The stock opened at HK$75 per share,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["06938"],"gpt_icon":0},{"id":"2601395597","title":"BRIEF-Suzhou Ribo Life Science Announces Offer Price Of HK$57.97 Per Share Under Global Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2601395597","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601395597?lang=en_us&edition=fundamental","pubTime":"2026-01-08 23:27","pubTimestamp":1767886065,"startTime":"0","endTime":"0","summary":"BRIEF-Suzhou Ribo Life Science Announces Offer Price Of HK$57.97 Per Share Under Global OfferingJan 8 (Reuters) - Suzhou Ribo Life Science Co Ltd 6938.HK:OFFER PRICE HK$57.97 PER SHARE UNDER GLOBAL OFFERINGFurther company coverage: 6938.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y916F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"gpt_icon":0},{"id":"1138627945","title":"New Stock Gray Market | RIBOLIFE-B (06938) Surges Over 12% in Early Gray Market Trading, Profit of HK$1,406 Per Board Lot","url":"https://stock-news.laohu8.com/highlight/detail?id=1138627945","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138627945?lang=en_us&edition=fundamental","pubTime":"2026-01-08 16:31","pubTimestamp":1767861077,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) is scheduled to list on the Hong Kong Stock Exchange on Friday, January 9, 2026. As of the latest update, gray market trading indicates a quote of HK$65, representing a significant...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"gpt_icon":0},{"id":"1180537540","title":"Caitong Securities: Leading Small Nucleic Acid Drug Firm Launches IPO, Sector Poised as Annual Healthcare Theme","url":"https://stock-news.laohu8.com/highlight/detail?id=1180537540","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180537540?lang=en_us&edition=fundamental","pubTime":"2026-01-06 10:00","pubTimestamp":1767664823,"startTime":"0","endTime":"0","summary":"According to a research report from Caitong Securities, against the backdrop of the global pharmaceutical industry's upgrade towards precision therapy, small nucleic acid drugs, as a third-generation...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK0276","159938","BK1574","601108","BK1515","BK1161","09939"],"gpt_icon":0},{"id":"1122355356","title":"Zhiton Hong Kong Stock Investment Diary | January 1","url":"https://stock-news.laohu8.com/highlight/detail?id=1122355356","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122355356?lang=en_us&edition=fundamental","pubTime":"2026-01-01 00:02","pubTimestamp":1767196965,"startTime":"0","endTime":"0","summary":"The following is the investment diary for Hong Kong-listed companies on January 1, 2026:","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02675","00501","02513","BK1128","01641","08610","03986","00100","09903","03636","06938"],"gpt_icon":0},{"id":"2595741179","title":"Suzhou Ribo Life Science Launches Hong Kong IPO to Raise HK$1.6 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2595741179","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595741179?lang=en_us&edition=fundamental","pubTime":"2025-12-31 09:39","pubTimestamp":1767145193,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science  launched its Hong Kong initial public offering on Wednesday, aiming to raise HK$1.59 billion.The life sciences company is offering 27,487,400 H shares at an indicative price of HK$57.97 per share, according to a Wednesday Hong Kong bourse filing.The offering comprises 2.7 million H shares for Hong Kong investors and 24.7 million H shares for international investors, subject to reallocation and the overallotment option.The company secured 11 cornerstone investors, who committed to subscribing to $100 million worth of IPO shares.The issuer expects to disclose the allocations on Jan. 8 and start trading on the Hong Kong bourse on Jan. 9.Net proceeds will primarily be used for the research and development of the company's core product RBD4059, as well as RBD5044 and RBD1016. Funds will also be used to fund the research and development of the company's preclinical assets.China International Capital Corporation Hong Kong, Citigroup Global Markets Asia, ICBC Internat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06938"],"gpt_icon":0},{"id":"2595411187","title":"BRIEF-Suzhou Ribo Life Science Says Number Of Offer Shares 27.5 MLN H Shares Under Global Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2595411187","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595411187?lang=en_us&edition=fundamental","pubTime":"2025-12-31 09:35","pubTimestamp":1767144959,"startTime":"0","endTime":"0","summary":"BRIEF-Suzhou Ribo Life Science Says Number Of Offer Shares 27.5 MLN H Shares Under Global Offering Dec 31  - SUZHOU RIBO LIFE SCIENCE 6938.HK:  UNDER GLOBAL OFFERING NUMBER OF OFFER SHARES 27.5 MILLION H SHARESNUMBER OF INTERNATIONAL OFFER SHARES 24.7 MILLION H SHARES UNDER GLOBAL OFFERINGOFFER PRICE UNDER GLOBAL OFFERING HK$57.97 PER H SHAREFurther company coverage: [ ] ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nFWN3Y00HU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ribolia.com","stockEarnings":[{"period":"1week","weight":0.0383},{"period":"1month","weight":0.3576},{"period":"ytd","weight":0.3576}],"compareEarnings":[{"period":"1week","weight":-0.0036},{"period":"1month","weight":0.036},{"period":"3month","weight":0.0225},{"period":"6month","weight":0.0536},{"period":"1year","weight":0.3578},{"period":"ytd","weight":0.0437}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Suzhou Ribo Life Science Co Ltd is a China-based company primarily engaged in the oligonucleotide research and development, with a focus on small interfering ribonucleic acid (siRNA) therapeutics. The Company’s main business is engaged in the oligonucleotide drug innovation focused on cardiovascular, metabolic, renal and liver diseases, as well as other therapeutic areas. The Company’s drug pipelines include RBD4059, RBD5044, RBD7022, RBD7007, RBD2080, RBD1119, RBD1016 and others. The Company mainly conducts its business in the domestic market.","exchange":"SEHK","name":"RIBOLIFE-B","nameEN":"RIBOLIFE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"RIBOLIFE-B(06938),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest RIBOLIFE-B(06938) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"RIBOLIFE-B,06938,RIBOLIFE-B股票,RIBOLIFE-B股票老虎,RIBOLIFE-B股票老虎国际,RIBOLIFE-B行情,RIBOLIFE-B股票行情,RIBOLIFE-B股价,RIBOLIFE-B股市,RIBOLIFE-B股票价格,RIBOLIFE-B股票交易,RIBOLIFE-B股票购买,RIBOLIFE-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"RIBOLIFE-B(06938),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest RIBOLIFE-B(06938) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}